165pranolazine before and during Trastuzumab Treatment, Prevents Cardiotoxicity in Mice.
نویسندگان
چکیده
N. Maurea1, C. Coppola2, G. Piscopo2, D. Rea3, F. Galletta2, C. Maurea2, I. Capasso4, C. Arra3, R.V. Iaffaioli5 Cardiology, INT Pascale Naples, Naples, ITALY Cardiology, National Cancer Institute, Pascale Foundation, Naples, ITALY Animal Experimental Research, National Cancer Institute, Pascale Foundation, Naples, ITALY Breast Oncology Division, National Cancer Institute, Pascale Foundation, Naples, ITALY Colorectal Oncology, National Cancer Institute, Pascale Foundation, Naples, ITALY
منابع مشابه
Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking
OBJECTIVE Considering that global left ventricular systolic radial strain is a sensitive technique for the early detection of left ventricular dysfunction due to antineoplastics and the analysis of segmental myocardial contractility, we evaluated this technique for early detection of trastuzumab-related cardiotoxicity by comparing it with cardiac structural damage. METHODS Groups of six mice ...
متن کاملTrastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice
Treatment with trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of Human Epidermal Growth Factor Receptor 2 (HER2), very successfully improves outcomes for women with HER2-positive breast cancer. However, trastuzumab treatment was recently linked to potentially irreversible serious cardiotoxicity, the mechanisms of which are largely elusive. This study repo...
متن کاملDuration of adjuvant trastuzumab treatment in routine practice.
BACKGROUND Trastuzumab is used for the adjuvant (postoperative) treatment of (HER2)-positive early breast cancer. The duration of treatment is set at one year. The goal of our study was to examine the effective duration of trastuzumab treatment in routine clinical practice. PATIENTS AND METHODS We performed a retrospective review of all patients with early breast cancer, treated with trastuzu...
متن کاملTrastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity.
Trastuzumab, a monoclonal antibody against the HER2 receptor, was recently approved for the treatment of metastatic breast cancer. However, 28% of patients receiving both an anthracycline and trastuzumab developed heart failure. Although HER2 overexpression has been associated with the development of cancer, HER2 receptors seem to be cardioprotective because they mediate the activation of impor...
متن کاملTrastuzumab-induced cardiotoxicity.
PURPOSE/OBJECTIVES To review trastuzumab-related cardiotoxic effects in the breast cancer adjuvant setting, present a system for pretreatment screening for cardiovascular risk factors, describe monitoring recommendations, provide a tool to facilitate adherence to monitoring guidelines, and discuss implications for patient education. DATA SOURCES Literature regarding cardiotoxicity and trastuz...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 25 suppl_4 شماره
صفحات -
تاریخ انتشار 2014